How COVID-19 changed medical device clinical trials forever

The success of remote clinical trial oversight opens the door to hybrid approaches and creates new possibilities for the future of trials.

[Image from Unsplash]


Because of the pandemic, virtually overnight, all players involved in medical device clinical trials had to pivot to virtual monitoring to keep trials going. What impact did remote trial oversight have on the quality, safety, and costs of clinical trials? What are the implications for the future?

A panel of experts from across the clinical trial ecosystem discussed these topics on a recent episode of DeviceTalks Tuesdays, sponsored by IMARC.

Panelists included Hamish Baird, clinical research president at Remington-Davis; Brandy Chittester, president of IMARC Research; Xavier Lefebvre, global VP of medical and regulatory operations at Medtronic; and Dr. Eric Kolodziej, corporate VP and global head of quality and regulator…

Read more
  • 0

Remington-Davis launches dedicated COVID-19 research unit in Ohio

[Image courtesy of Google Maps]

Clinical research outfit Remington-Davis recently announced that it has launched a dedicated 3,000 ft2 space in Columbus, Ohio for COVID-19 clinical trials.

The space includes six private overnight rooms, patient lounge, dedicated laboratory, oxygen therapy and more. Participants must be 18 or older with COVID-19 symptoms and have a laboratory-confirmed SARS-CoV2 infection.

Clinical trials have started for REGN-COV2, Regeneron’s anti-viral antibody cocktail for the treating and preventing COVID-19.

Read more
  • 0